GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Thiogenesis Therapeutics TTI.V · CAD

N/A · TSX Venture · 🇨🇦 Canada

Compare

0.64

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2025

Net income

−C$7.4m

FY2019FY2025

Free cash flow

−C$6.0m

FY2019FY2025

Shareholders' equity

C$574,377

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Research and developmentC$5.8mC$2.2mC$4.2mC$1.1mC$1.4mC$499,702C$164,579
Operating income−C$7.4m−C$3.6m−C$5.2m−C$2.0m−C$224,678−C$92,653−C$103,779
Net income−C$7.4m−C$3.1m−C$5.1m−C$3.9m−C$224,457−C$92,678−C$103,668
Diluted earnings per share-0.14-0.07-0.11-0.10-0.01-0.00-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsC$1.8mC$4.0mC$7.2mC$6.3mC$3.4mC$146,431C$413,420
Total liabilitiesC$1.2mC$557,876C$1.7mC$307,151C$3.5mC$63,080C$17,278
Shareholders' equityC$574,377C$3.4mC$5.5mC$6.0m−C$61,066C$83,351C$396,142
Shares outstanding52m46m45m39m28m28m28m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−C$6.0m−C$3.9m−C$3.2m−C$2.1m−C$67,076−C$50,711−C$282,102
Free cash flow−C$6.0m−C$3.9m−C$3.2m−C$2.1m−C$67,076−C$50,711−C$282,102

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−C$1.5m−C$917,825−C$1.7m−C$2.4m−C$1.8m−C$1.3m−C$1.3m−C$677,782
Net income−C$1.5m−C$911,820−C$1.7m−C$2.4m−C$1.9m−C$1.4m−C$1.1m−C$656,856
Diluted earnings per share-0.02-0.02-0.03-0.05-0.04-0.03-0.02-0.01
Cash from operations−C$1.0m—−C$1.0m−C$2.0m−C$1.0m———
Total assetsC$7.4mC$1.0mC$1.8mC$3.6mC$1.9mC$3.1mC$4.0mC$4.3m
Shareholders' equityC$6.7m−C$226,569C$574,377C$2.2mC$456,835C$2.1mC$3.4mC$4.1m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income55.3%140.1%—
Net income23.7%140.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-4.5-8.8-6.6-5.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.